Emergent rises on $24 million anthrax vaccine order
01/09/2026 13:16
BUZZ-Emergent rises on $24 million anthrax vaccine order ** Shares of drugmaker Emergent BioSolutions EBS.N rise 3.8% to $6.33 premarket
** Co receives an order worth about $24 million from the U.S. Biomedical Advanced Research and Development Authority to supply its Cyfendus vaccine for anthrax preparedness
** Cyfendus, approved in 2023, is a two-dose vaccine used with antibiotics in adults after suspected or confirmed exposure to anthrax, a potentially deadly bacterial infection
** Award follows an order worth up to $21.5 million earlier this year to supply co's BioThrax anthrax vaccine
** As of last close, EBS down 50.7% YTD
(Reporting by Kunal Das in Bengaluru)